Home > Academic Announcements > (Oct. 14) Frontiers in Pharmaceutical Sciences Lecture Series - No. 157

(Oct. 14) Frontiers in Pharmaceutical Sciences Lecture Series - No. 157

Last updated :2013-10-12

Topic: The Research Staus & Prospect of the Therapeutic Antibodies
Speaker: ZHU Zhenping
, PhD, Executive Vice President, Global Head, Biopharmaceuticals, Kadmon Corporation, New York, and President & CEO, Kadmon (China)
Chair: Prof. Min Huang, School of Pharmaceutical Science,Sun Yat-sen University
Time: Monday, 14thOctober, 2013, 3:30 PM
Venue: 125 Meeting Room, School of Pharmaceutical Sciences, East Campus, SYSU

Introduction of the speaker:

Dr. ZHU Zhenping is currently Executive Vice President, Global Head, Biopharmaceuticals, Kadmon Corporation, New York, and President & CEO, Kadmon (China). Prior to joining Kadmon, Dr. Zhu was Global Head/Vice President, Protein Sciences and Design, at Novartis from February 2009 to July 2010. At Novartis, he was a member of the Novartis Biologics Leadership Team, and had the overall leadership responsibility for the discovery and design of novel biologic drugs, including monoclonal antibodies, recombinant proteins and engineered molecules, that address diseases of high unmet need. Prior to joining Novartis, Dr. Zhu was Vice President of Antibody Technology and Immunology, at ImClone Systems, a Manhattan-based biopharmaceutical company dedicated to developing and commercializing breakthrough biologic medicines in the area of oncology. Dr. Zhu joined ImClone in November 1996 and was responsible for ImClone’s research programs in pipeline discovery, antibody technology and immunology - focusing on discovering, engineering and optimization of therapeutic antibodies and novel antibody-like molecules for various oncology indications. His efforts led to the discovery of a large panel of antibodies that entered clinical development at ImClone, including IMC-1121B (anti-VEGFR2, phase III) and IMC-11F8 (anti-EGFR, phase III), and a panel of other antibodies that are in phase I/II and late stages of preclinical development. He was a member of ImClone’s Research and Development Review Committee (RDRC) and Research Management Committee (RMC).

Dr. Zhu received his medical training from Jiangxi Medical College (Nanchang, China), his MSc in Pharmacology from Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC, Tianjin, China), and his PhD in Immunology and Pathology from Dalhousie University (Halifax, NS, Canada). During 1993 to 1996, he worked as a postdoctoral fellow in antibody engineering in the Department of Molecular Oncology, Genentech, Inc. (South San Francisco, CA, USA). He passed the US Medical Licensing Examination (USMLE) and secured the Education Commission for Foreign Medical Graduates (ECFMG) certification in 1996. From 1996 to 2006, Dr. Zhu held an adjunct professor position in the State Key Laboratory of Experimental Hematology at Institute of Hematology, CAMS & PUMC. Dr. Zhu has been working in the areas of antibody technologies / applications and cancer bio-therapeutics for the past 25 years and has authored or co-authored over 190 peer-reviewed scientific publications, including original research papers, invited reviews and book chapters. He is also a frequent invited speaker at various international life science conferences. He is listed as the inventor or co-inventor of more than 50 US and international issued patents and patent applications. Dr. Zhu co-organized and chaired the First (September 2000, Tianjin, China), the Second (October 2005, Beijing, China), and the Third (March 2009, Taipei) China International Symposiums on Antibody Engineering and Antibody-based Therapeutics, each was attended by 200 to 400 scientists with 35 to 40 invited speakers who are the internationally renowned experts in the antibody field. He is a member of the BayHelix Group, Sino-American Pharmaceutical Association (SAPA), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH).

All are welcome!